Hemostemix Historical Cash Flow

HEM Stock  CAD 0.08  0.01  5.88%   
Analysis of Hemostemix cash flow over time is an excellent tool to project Hemostemix future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Net Borrowings of 1.4 M or Stock Based Compensation of 142.4 K as it is a great indicator of Hemostemix ability to facilitate future growth, repay debt on time or pay out dividends.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Hemostemix latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Hemostemix is a good buy for the upcoming year.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemostemix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Hemostemix Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Hemostemix balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Hemostemix's non-liquid assets can be easily converted into cash.

Hemostemix Cash Flow Chart

At this time, Hemostemix's Sale Purchase Of Stock is fairly stable compared to the past year. Change In Cash is likely to climb to about 20.7 K in 2024, whereas Stock Based Compensation is likely to drop slightly above 142.4 K in 2024.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Depreciation

Depreciation indicates how much of Hemostemix value has been used up. For tax purposes Hemostemix can deduct the cost of the tangible assets it purchases as business expenses. However, Hemostemix must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Capital Expenditures

Capital Expenditures are funds used by Hemostemix to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Hemostemix operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Investments

Securities or assets acquired for generating income or appreciating in value, not used in daily operations.
Most accounts from Hemostemix's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Hemostemix current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemostemix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
At this time, Hemostemix's Sale Purchase Of Stock is fairly stable compared to the past year. Change In Cash is likely to climb to about 20.7 K in 2024, whereas Stock Based Compensation is likely to drop slightly above 142.4 K in 2024.

Hemostemix cash flow statement Correlations

0.26-0.210.14-0.410.08-0.05-0.240.480.02-0.17-0.530.310.66-0.340.18
0.26-0.14-0.160.02-0.35-0.7-0.620.61-0.06-0.550.180.690.23-0.190.01
-0.21-0.14-0.790.410.310.130.16-0.050.830.780.44-0.07-0.75-0.380.22
0.14-0.16-0.79-0.43-0.030.290.04-0.21-0.7-0.36-0.640.070.770.59-0.11
-0.410.020.41-0.430.29-0.090.10.120.250.430.84-0.07-0.5-0.08-0.12
0.08-0.350.31-0.030.290.390.17-0.350.590.49-0.2-0.09-0.130.30.61
-0.05-0.70.130.29-0.090.390.16-0.490.070.57-0.320.03-0.040.31-0.14
-0.24-0.620.160.040.10.170.16-0.08-0.020.44-0.01-0.71-0.250.130.04
0.480.61-0.05-0.210.12-0.35-0.49-0.08-0.22-0.160.220.360.2-0.4-0.38
0.02-0.060.83-0.70.250.590.07-0.02-0.220.560.16-0.02-0.56-0.330.66
-0.17-0.550.78-0.360.430.490.570.44-0.160.560.24-0.2-0.53-0.120.03
-0.530.180.44-0.640.84-0.2-0.32-0.010.220.160.24-0.06-0.64-0.32-0.34
0.310.69-0.070.07-0.07-0.090.03-0.710.36-0.02-0.2-0.060.280.05-0.12
0.660.23-0.750.77-0.5-0.13-0.04-0.250.2-0.56-0.53-0.640.280.090.01
-0.34-0.19-0.380.59-0.080.30.310.13-0.4-0.33-0.12-0.320.050.09-0.01
0.180.010.22-0.11-0.120.61-0.140.04-0.380.660.03-0.34-0.120.01-0.01
Click cells to compare fundamentals

Hemostemix Account Relationship Matchups

Hemostemix cash flow statement Accounts

201920202021202220232024 (projected)
Change In Cash(1.4M)233.9K(38.5K)(83.7K)19.7K20.7K
Stock Based Compensation333.3K2.3M361.6K178.7K149.9K142.4K
Free Cash Flow(3.4M)(6.0M)(3.5M)(6.1M)(1.5M)(1.6M)
Change In Working Capital1.0M(825.7K)2.8M(1.7M)554.7K491.2K
Begin Period Cash Flow1.5M24.1K258.0K219.4K135.7K129.0K
Other Cashflows From Financing Activities3.9M1.4M2.6M5.3M(78.1K)(74.2K)
Other Non Cash Items105.0K106.0K(114.3K)172.8K335.9K352.7K
Total Cash From Operating Activities(3.4M)(6.0M)(3.5M)(6.1M)(1.5M)(1.6M)
Change To Account Receivables115.5K(2.0M)1.7M203.8K113.9K119.6K
Change To Operating Activities1.2M40.5K(2.0M)13.5K12.2K12.8K
Net Income(4.9M)(7.8M)(6.3M)(5.2M)(2.5M)(2.6M)
Total Cash From Financing Activities2.0M6.2M3.3M6.0M1.5M1.4M
End Period Cash Flow24.1K258.0K219.4K135.7K155.4K147.6K
Change To Netincome1.6M438.2K2.6M838.4K964.1K1.0M
Change To Liabilities910.7K1.2M0.0(1.7M)(1.5M)(1.5M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Hemostemix Stock Analysis

When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.